Azole-resistant aspergillosis

Area of Science:

• Medical Mycology
• Antimicrobial Resistance

Background:

• Emerging azole-resistance in Aspergillus fumigatus presents a significant clinical challenge for managing aspergillosis.
• Resistance develops through individual azole treatment or environmental fungicide exposure.
• The cyp51A gene mutations are the primary molecular mechanism driving azole resistance.

Purpose of the Study:

• To highlight the increasing problem of azole-resistance in Aspergillus fumigatus.
• To discuss the dual routes of resistance development: patient treatment and environmental exposure.
• To underscore the lack of clinical guidelines and supporting evidence for treating azole-resistant aspergillosis.

Main Methods:

• Review of current literature on azole-resistance mechanisms in Aspergillus fumigatus.
• Analysis of the implications of environmental fungicide exposure on resistance.
• Assessment of the current clinical and pre-clinical evidence for treatment strategies.

Main Results:

• Azole-resistance in Aspergillus fumigatus is an increasing global health issue.
• Environmental fungicide exposure is a worrying factor, potentially impacting all patient groups.
• Mutations in the cyp51A gene are the key molecular drivers of resistance.

Conclusions:

• Azole-resistant aspergillosis requires urgent attention due to limited treatment options.
• Environmental resistance development poses a broad risk, irrespective of patient azole exposure history.
• Further research and clinical guidelines are crucial for effective management.